Introduction
============

The mechanisms underlying the metabolic derangements observed in many, but not all, obese patients are still only partially understood, with several authors suggesting the need to differentiate between 'healthy\' and 'unhealthy\' obese subjects, even at early ages.^[@bib1]^ Tissue resistance to insulin\'s actions (insulin resistance (IR)) has been largely postulated as the initial impairment underlying the onset of the metabolic comorbidities in these patients. Moreover, IR has been suggested to be the cornerstone for the pathophysiological interpretation of the originally named X-syndrome.^[@bib2]^

The assessment of IR is still a matter of debate, particularly in the pediatric setting, as most of the indexes and proposed diagnostic criteria are based on those developed in adults and their application in children is far from being unanimously accepted. The so considered 'gold-standard\' technique for the measurement of IR is the euglycemic-hyperinsulinemic clamp, but its use is mainly restricted to investigational facilities and is normally unavailable in the clinical setting. The usual clinic work-up aims to estimate the presence of IR by using some of its surrogate markers in both fasting and post-ingestion serum samples, with the latter being a better estimation of IR.^[@bib3]^

The importance of IR in the interpretation of obesity-associated metabolic derangement is particularly relevant in children, as their developmental characteristics (that is, they continue to grow longitudinally with tissue expansion and plasticity, including adipose tissue) determine substantial differences in their metabolic adaptation to obesity.^[@bib4]^ One of the most striking differences with adult obesity is that in childhood obesity, impairment of fasting glucose levels is usually absent and if present, it is a delayed finding. Indeed, a rise in insulinemia, both fasting and after glucose ingestion, can be identified as the very initial step of carbohydrate metabolism impairment in obese children.^[@bib5]^

On these bases, the study of the metabolic pathways potentially related to insulin sensitivity and the presence or absence of IR in obese children could help to understand its underlying pathophysiological mechanisms. Metabolomic strategies appear to be a valuable tool to achieve these objectives; indeed, metabolomics allows the interpretation of complex metabolic interactions occurring at a molecular level by providing a more thorough readout of the phenotype at a specific moment.^[@bib6],\ [@bib7]^ Several studies using metabolomics have highlighted the presence of a metabolic signature associated to obesity and IR, and report changes in metabolic profiles affecting central carbon metabolism (CCM), including glycolysis and the tricarboxylic acid cycle, amino acid and lipid pathways.^[@bib8],\ [@bib9]^ However, conversely to adults, few studies have evaluated IR in obese children.

In the present study, we devised a high throughput and data-driven approach to investigate the mechanisms underpinning obesity-associated hyperinsulinemia in children and to select a subset of representative biomarkers. We then employed a targeted strategy to test and validate the predictive capability of these biomarkers in a larger independent cohort.

Subjects and methods
====================

Subjects
--------

### First analysis: fingerprinting study

Sixty prepubertal (Tanner stage I) obese (OB, BMI\>+2 SDS according to Spanish standards,^[@bib10]^ also\>+2 SDS according to the IOTF references for children) Caucasian children (30 girls/30 boys, 50% IR and 50% non-IR in each group) were studied. The anthropometric and metabolic characteristics of the whole cohort, and the IR and non-IR subgroups are displayed in [Table 1](#tbl1){ref-type="table"}.

### Second analysis: validation study

One hundred prepubertal (Tanner stage I) obese (OB, BMI\>+2 SDS according to Spanish standards,^[@bib10]^ also\>+2 SDS according to the IOTF references for children) Caucasian children (50 girls/50 boys, 50% IR and 50% non-IR in each group) were studied. The anthropometric and metabolic characteristics of the whole cohort and the IR and non-IR subgroups are displayed in [Table 1](#tbl1){ref-type="table"}.

Methods
-------

All patients consulted the Department of Endocrinology of the Hospital Infantil Universitario Niño Jesús for being overweight. This is a monographic pediatric hospital for national referral, and thus receives patients from throughout Spain. They were studied to rule-out any underlying pathological condition before enrollment in the study. BMI was recorded and standardized. An oral glucose tolerance test (OGTT; 1.75 g of glucose/kg; maximum 75 g) was performed after an overnight fast with blood samples being obtained at 0, 30, 60 and 120 min for glucose and insulin measurements. Fasting samples were used for HbA1c and lipid profile analysis. Venous blood samples were collected between 08:00 and 09:00 hours after a 12-h overnight fast. After 30 min clotting at room temperature, samples were then centrifuged at 4°C and the serum separated and immediately frozen at 80°C until assayed, as previously reported.^[@bib11]^

Patients were classified as IR if they met one or more of the following criteria during the OGTT: fasting insulin\>15 μU ml^−1^; peak insulin\>150 μU ml^−1^ or insulin\>75 μU ml^−1^ 120′ after glucose ingestion.^[@bib12]^ The area under the curve for glucose and insulin throughout the OGTT was calculated according to the formula: 0.25 × fasting value+0.5 × 30′value+0.75 × 60′value+0.5 × 120′value.^[@bib13]^ HOMA index was calculated as follows: glucose (mg dl^−1^) × insulin (μU ml^−1^)/405 and whole body insulin sensitivity index as: 10 000/√ fasting glucose × fasting insulin × mean glucose in the OGTT × mean insulin in the OGTT.^[@bib3]^

Untargeted and targeted metabolomics analyses
---------------------------------------------

### Fingerprinting study

Metabolite extraction and metabolic fingerprinting were achieved by using a multiplatform-based untargeted metabolomics approach that employs a combination of analytical techniques such as liquid chromatography--mass spectrometry (LC--MS), capillary electrophoresis--mass spectrometry (CE--MS) and gas chromatography--mass spectrometry (GC--MS) from Agilent Technologies (Madrid, Spain) as described previously.^[@bib14],\ [@bib15],\ [@bib16]^ Samples were prepared and coded such that they were analyzed in random order with the analyst being unaware of the experimental group to avoid any bias. Data quality was assured by using quality control (QC) samples as reported.^[@bib17]^ See [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"} for further details.

### LC--MS and CE--MS data pre-processing

Data were pre-processed using MassHunter Qualitative Analysis (MH Qual B.06.00, Agilent Technologies) and Mass Profiler Professional (MPP B.02.00, Agilent Technologies) software as previously reported.^[@bib14],\ [@bib15]^ The resulting data matrix was then filtered through the Mass Profiler Professional software by retaining the features present in 100% of QC samples with a coefficient of variation (relative s.d., RSD) below 30%, and the features present in 100% of the samples of at least one of the groups under study. Finally, the CE data were normalized respect with to the IS (methionine sulphone). See [Supplementary Experimental Procedure](#sup1){ref-type="supplementary-material"} for further details.

### Data pre-processing and compound identification GC--MS analysis

Data were pre-processed as previously reported.^[@bib16]^ In brief, Automated Mass Spectrometry Deconvolution and Identification System (AMDIS version 2.71, <http://chemdata.nist.gov/mass-spc/amdis/downloads/>) were employed to deconvolute and to simultaneously identify the eluted compounds. Metabolites were identified by comparing their RT, RI and the mass fragmentation patterns with those available in an in-house library comprehensive of both the NIST mass spectral database (version 2008) and Fiehn RTL library (version 2008). Then, MPP software was used to align the data from all samples. The resulting data matrix was then filtered through the MPP software by retaining the features present in 100% of QC samples with a coefficient of variation (CV or relative s.d.) below 40%, and the features present in 100% of the samples of at least one of the groups under study. Finally, data were normalized with respect to the IS (methyl stearate).

### Compound identification LC--MS and CE--MS analyses

To putatively identify only the statistically significant compounds, their accurate mass was searched against public databases, that is, METLIN (<http://metlin.scripps.edu>), KEGG (<http://genome.jp/kegg>), LIPIDMAPS (<http://lipidmaps.org>) and HMDB (<http://hmdb.ca>). Afterwards, the identification was confirmed by means of standards (CE--MS data) and through the interpretation of the MS/MS spectra acquired in a subsequent LC/MS/MS analysis carried out using the same chromatographic conditions outlined previously. In addition, to increase the reliability of metabolite identification, the match score between the experimental isotopic pattern distribution and the compound formula was computed by MH Qual software.

### Validation study

Metabolite quantification was performed by a targeted metabolomics approach by using LC--MS and GC--MS from Agilent technologies as described.^[@bib18]^ See [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for further details.

Statistical analysis
--------------------

### Fingerprinting study

Statistical analysis was carried out by univariate (UVA, MATLAB R2015 software (Mathworks, Inc., Natick, USA)) and multivariate analyses (MVA, SIMCA P+ 12.0.1 software (Umetrics, Umea, Sweden)). For the UVA, parametric (unpaired *t*-test) or non-parametric (Mann−Whitney *U* test) tests with a Benjamini--Hochberg False Discovery Rate *post hoc* correction (*q* =0.05) were applied. For the MVA, data processing strategies (that is, normalization, scaling among others) were employed to improve the overall quality of data as reported,^[@bib19]^ and finally log-transformed and Pareto scaled (CE--MS and LC--MS) or ultraviolet scaled (GC--MS) data were used to create multivariate models. Afterwards, unsupervised (principal components analysis) and supervised (orthogonal partial least squares discriminant analysis, OPLS-DA) analyses were performed to check trends, outliers and to select the variables responsible for the separation showed by the models. Then, the models were statistically validated by the cross-validation tool, using the leave-1/3-out approach to exclude model overfitting. In addition, boys and girls were considered separately to evaluate the contribution of the sex variable. In this case, both UVA and MVA were performed by following the same procedure above outlined. Finally, the percentage of change for the relevant variables resulting from both UVA and MVA was calculated as follows: ((average value in the tested group-average value in reference group)/ average value in reference group) × 100. In the case of non-normally distributed data, the median instead of the mean was employed.

### Validation study

Parametric (unpaired *t*-test) or non-parametric (Mann−Whitney *U* test) tests with a Benjamini--Hochberg *post hoc* correction (*q*=0.05) were performed in MATLAB.

Results
=======

Fingerprinting study
--------------------

Metabolic fingerprinting yielded the detection of 72 279 potential compounds in serum (LC: 67 617 CE: 4 582 GC: 80). Data filtration was applied by reducing the matrix to 818 compounds (ESI+: 257, ESI-: 315, CE: 196, GC: 50). Then, multivariate and UVA statistical analyses were applied to investigate the comparison between obese children with and without IR. Principal components analysis assured data quality by plotting a clear QC sample clustering ([Figure 1a](#fig1){ref-type="fig"}, [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The supervised analyses by OPLS-DA elucidated the discrimination between obese children with IR (group 2) and without IR (group 1). Remarkably, the separation was magnified when only females were considered indicating prepubertal sex differences ([Figures 1b and c](#fig1){ref-type="fig"}, [Supplementary Figures 2 and 3](#sup1){ref-type="supplementary-material"}). Subsequently, the OPLS-DA models were validated and the samples were correctly predicted for 86% in LC (ESI +/-), 83% in GC, 85% in CE. Afterwards, the compounds responsible for the separation found by the models were selected according to the S-plot and the Jack-knife confidence interval (*P*\<0.05). In addition, *P*-values were computed for the comparison between groups (1 vs 2) in the whole cohort (*n*=60) and then in males (*n*=30) and females (*n*=30). [Table 2](#tbl2){ref-type="table"} includes the 47 identified compounds that showed statistically significant between-group differences after adjustment for multiple testing (that is, *P*\<0.05 and *q*=0.05). In contrast, 38 out of the 85 compounds statistically significant after adjustment for multiple testing (that is, *P* \<0.05 and *q*=0.05) remained unidentified. Among the identified compounds, there were 15 amino acids and derivatives, 17 phospholipids (mainly lyso-forms), 3 organic acids, 2 bile acids, 5 fatty acyls, 2 carnitines and 3 other compounds. Bile acids (BAs) and some lysophospholipids (LPs) exhibited the most prominent changes. In contrast, the majority of the metabolites, in particular the amino acids and derivatives, showed subtle difference with a percentage of change between the groups of \~30%. Finally, we observed the same tendency of variation in all comparisons (overall, females and males). Further details are included in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Among the compounds showing statistically significant differences between groups in this preliminary study, the 16 most representative metabolites were selected for quantification and verification in a larger independent cohort (IR=50 and non-IR=50). These metabolites included: glycodeoxycholate, taurodeoxycholate, acetylcarnitine (C02-carnitine), 2-methylbutyroylcarnitine (C05-carnitine), pyruvate, 3-hydroxybutyrate, isoleucine, leucine, valine, alanine, phenylalanine, proline, tryptophan, tyrosine, pyroglutamate and piperidine. In addition, the 11 acylcarnitines and 6 amino acids present in the Internal Standard mix (MassChrom Internal Standard Labelled) were included in the validation study.

Validation study
----------------

After quantification of the metabolites, the *P*-value was computed for comparison between obese children with IR and without IR (1 vs 2) by considering all samples (*n*=100) and males (*n*=50) and females (*n*=50) separately. In [Table 3](#tbl3){ref-type="table"}, only the metabolites that showed significant differences between IR/no-IR after adjustment for multiple testing (that is, *P*\<0.05 and *q*=0.05) are listed. When the overall cohort is considered, all compounds except C05 and C02-carnitines were confirmed. These differences between groups were more evident in females when the sexes were analyzed separately. Concerning acylcarnitines three, that is, free carnitine (C00), propionylcarnitine (C03) and butyrylcarnitine (C04) were found to be increased significantly in IR for the whole cohort and females, whereas in males only C03-carnitine was increased significantly. Notably, among all compounds only alanine and C03-carnitine were common in all comparisons. Finally, we observed a tendency to increase for the majority of the metabolites, except 3-hydroxybutyrate, free carnitine and pyroglutamate, in the subjects with IR compared with those without IR.

Discussion
==========

In this study, we have applied a comprehensive untargeted metabolic fingerprinting protocol to gain a deeper understanding of the metabolic pathways potentially associated with alterations in insulin signaling in prepubertal obese children by comparing those with and without IR (1 vs 2). As depicted in [Figure 2](#fig2){ref-type="fig"}, the findings of this study can be pooled into three major observations: (1) CCM is one of the metabolic pathways that is most influenced by disturbances in insulin signaling; (2) inflammatory events are enhanced in the presence of IR; and (3) microbiota influence the host metabolism, as pointed out by the marked changes in BAs.

Central carbon metabolism
-------------------------

As expected, CCM, which includes glycolysis, tricarboxylic acid and acylcarnitine metabolism was unveiled as the most altered process in obese children with IR. Indeed, the majority of metabolites statistically differing between groups belong to one or several pathways involved in CCM. Moreover, even though the percentage of change between the insulin resistant and non-insulin resistant state is relatively small, we observed an overall increase in amino acids such as alanine, proline and aromatic amino acids (ArAAs; that is, phenylalanine, tyrosine and tryptophan) and branched chain amino acids (BCAA; that is, leucine, isoleucine and valine) in IR. The relationship between increased amino acids and IR has been previously reported, highlighting higher proteolysis and lower amino acid catabolism induced by hyperinsulinemia; indeed, some amino acids have been suggested as both markers and effectors of IR.^[@bib20],\ [@bib21]^ Among these, the increased levels of BCAAs and related metabolites (ArAA, glutamate, and C3 and C5 acylcarnitines) have consistently emerged in recent years as biomarker of obesity and IR. In 2009, Newgard *et al.* suggested this cluster to be the metabolic signature of obese subjects and associated their increase with the onset of IR in mice ingesting a high-fat diet.^[@bib8]^ This theory has been corroborated by subsequent studies in lean subjects with or without IR and in obese subjects with IR after bariatric surgery or dietary intervention.^[@bib22],\ [@bib23]^ These studies highlighted a discriminant capability for BCAA and related metabolites, in case of obesity and IR, and a further predictive capability for the onset of complications such as cardiovascular disease and T2DM (up to 12 years in advance) and for the effectiveness of treatment.^[@bib24],\ [@bib25]^

Although the involvement of the BCAAs and related metabolites in IR is clear, the mechanisms underlying the onset of IR is still a matter of debate. Two major hypotheses have emerged that propose two pathways associated to IR: mammalian target of rapamycin complex 1 signaling and derangement of BCAA metabolism.^[@bib26]^ The first hypothesis postulates that permanent activation of the mammalian target of rapamycin complex 1/serine kinases pathway mediated by BCAA inactivates insulin receptor substrate-1 and insulin receptor substrate-2, and stimulates pancreatic beta cells to enhance insulin secretion resulting in hyperinsulinemia, beta cell exhaustion and thus risk to develop T2DM. However, the sole activation of this pathway might not be sufficient to cause IR and the subsequent complications, but rather a contributing factor in conjunction with inflammation and hyperinsulinemia. In contrast, the second model identifies the toxic metabolites derived from disrupted BCAA metabolism as the cause of IR. Indeed, it has been reported that increased BCAAs (coming from the diet, low catabolic rate in adipose tissue and insulin-induced proteolysis, among others) promotes their catabolism in liver and skeletal muscle and that their by-products (that is, ketoisocaproic acid, short-chain acylcarnitines and their intermediates) affect glucose and fatty acid oxidation by yielding incompletely oxidized substrates that are involved in mitochondrial stress and impaired insulin signaling.^[@bib9]^

Consistent with this model, we found that in addition to the elevation in BCAA, IR obese children had increased levels of ketoisocaproic acid, C3 and C4 acylcarnitines and decreased free carnitine. Moreover, we observed an increased level of ArAAs, which are precursor of serotonin (from tryptophan) and catecholamines (from phenylalanine and tyrosine) in the brain.^[@bib27]^ They compete with the BCAA for transport into mammalian cells; therefore, their elevation in serum may indicate a disruption in their transportation into the brain due to an excess of BCAA.

We also observed elevated alanine levels in association with IR in every comparison set studied. Alanine is synthesized in skeletal muscle from pyruvate and other amino acids (mainly BCAAs) via the alanine-glucose cycle. In the liver it is then converted back to pyruvate, which is an intermediate for both the tricarboxylic acid cycle and gluconeogenesis.^[@bib28]^ Furthermore, we found an increase in pyruvate and a decrease in 3-hydroxybutyrate, consistent with enhanced glycolysis and reduced ketone body production in the presence of hyperinsulinemia. Hence, our study provides evidence of altered CCM in young children with IR and obesity mainly associated to increased levels of BCAA and related metabolites, which is consistent with the models proposed for adolescents and adults.

Inflammatory processes
----------------------

Chronic low-grade inflammation has been proposed as a possible link between obesity and IR; their interplay has been extensively investigated unveiling an interchangeable cause-effect relationship. Indeed, it has been reported that obesity and IR trigger inflammation by enhancing the release of free fatty acids and cytokines from adipose tissue and macrophages.^[@bib29]^ In the opposite direction, inflammation alters the expression of insulin-related genes leading to impaired insulin signaling.^[@bib30]^ Consistent with the literature, we found high levels of LPs characterizing the insulin resistant state. LPs can be generated from glycerophospholipids by the action of phospholipase A2 and reactive oxygen species, and both have been associated with increased inflammatory status.^[@bib31],\ [@bib32]^ Among the LP related compounds, the subgroup of lysophosphocholine is of particular interest, due to both its pro-inflammatory effect and its contribution to insulin signaling impairment.^[@bib33],\ [@bib34]^

In addition to the increase in pro-inflammatory metabolites, we observed a parallel decrease in metabolites such as bilirubin, nitro-octadecenoate, docosahexaenoate and docosapentanoate, all of which have anti-inflammatory properties. Bilirubin exhibits antioxidant activity and inhibits lipid and protein peroxidation;^[@bib35]^ whereas nitro-octadecenoate acts as an endogenous anti-inflammatory mediator by interacting with macrophages both by down-regulating lipoprotein-associated phospholipase A2 expression^[@bib36]^ and by inhibiting cytokine release after lipopolysaccharide-stimuli.^[@bib37]^ Docosahexaenoate and docosapentanoate, polyunsaturated fatty acids of the omega-3 series, reduce inflammation-related mediators^[@bib38]^ and can also influence the IR state. Indeed, it was recently reported that IR is decreased in obese children and adolescents by dietary supplementation with omega-3-polyunsaturated fatty acids.^[@bib39],\ [@bib40]^ Our results highlight that the unbalanced proportion of pro-inflammatory vs anti-inflammatory effectors characterizing the obese children is exacerbated in the presence of IR driven hyperinsulinemia.

Microbiota influence
--------------------

Glycodeoxycholate and taurodeoxycholate are greatly increased in the obese subjects with IR when compared with their non-insulin resistant counterparts. These compounds presented the most marked changes, unveiling the influence of the gut microbiota on the host metabolism. Indeed, their presence in plasma is mediated by the action of the microbiota that transforms cholate, conjugated with glycine or taurine, into secondary BAs that are reabsorbed from the distal ileum through the enterohepatic circulation. These secondary BAs then act as signaling molecules through activation of the Farsenoid X receptor and the G-protein coupled receptor TGR5 in peripheral organs (that is, liver and adipose tissue), which regulate the lipid and glucose homeostasis of the host.^[@bib41]^ In addition to BAs, piperidine, the by-product of amino acid degradation mediated by the microflora, is also increased in the insulin resistant group. Together these changes in metabolites indicate involvement of the gut microbiota and suggest that it contributes to the development of obesity and its complications. Indeed, compelling evidence has linked the gut microbiota to obesity and obesity-associated inflammation, and IR both in animals and in humans.^[@bib42]^ In addition to the aforementioned effect of secondary BAs, the microbiome increases the energy harvest from the diet by generating short-chain fatty acids from undigested starch and modulates energy storage through angiopoietin-like protein4, which is related to the uptake of triglycerides.^[@bib43]^ Furthermore, the microbiome can trigger inflammation and subsequent impairment of insulin signaling via a metabolic endotoxemia due to increased production of the endotoxin (lipopolysaccharide) present on the cell wall of Gram-negative bacteria. Indeed, the gut microbiota, which is altered by obesity, modulates intestinal permeability and increases the passage of lipopolysaccharide into the circulation, which in turn stimulates the pro-inflammatory signaling cascade.^[@bib42],\ [@bib44]^

Obese children are reported to have altered microbiota compared with their lean counterparts^[@bib45]^ and the initial composition of the microbiota may have predictive capability for the effects of dietary intervention^[@bib46]^ and for the onset of obesity in overweight children.^[@bib47]^ Our findings suggest a possible alteration in the microflora in obese children, and they provide additional information regarding the insulin resistant state that seems to be characterized by a magnified contribution of the microbiome on the host metabolome when compared with the non-IR obese state.

Thus, the involvement of the three processes underscored by the present study highlights the multifactorial nature of the interaction between obesity and IR, suggesting that several pathways are altered early on and interact at multiple levels in the development of IR. These pathways and relative metabolites might be a valuable tool in preventing disease progression. Recent studies have described metabolic signatures of human diseases, including diabetes, that occur in response to alterations in the metabolism of amino acids, gut microbiota by-products and lipids^[@bib8],\ [@bib48],\ [@bib49],\ [@bib50],\ [@bib51]^ similar to what occurred at a lesser extent in obese children with IR. This suggests their possible use as a hallmark for the early onset of complications. Current recommendations on early detection of T2DM in children emphasize the difficulties in distinguishing T2DM from T1DM in early stages, particularly in some patients, given the high prevalence of obesity and the possibility of ketoacidosis at the onset of T2DM. Analysis of the metabolites shown by the present study to be, altered in cases of obesity with IR, could be implemented in clinical practice to identify high-risk individuals earlier to delay or prevent disease onset and additionally to allow personalized preventive and therapeutic strategies.

Our study highlights the effect of sex on the IR-mediated alterations; indeed, the significance of these alterations was intensified when females were investigated separately. Girls with IR showed an overall increased concentration of acylcarnitines and amino acids (mainly BCAA) in serum. Previous studies have reported a higher incidence of IR in girls before puberty^[@bib52],\ [@bib53]^ due to differences of sex-linked genes that may explain this intrinsic difference. These findings suggest a female susceptibility toward IR-mediated alterations that is consistent with our results on the metabolic profile of obese girls with IR. In boys the observed changes associated with IR were less intense than in girls. This finding is in contrast to previous studies showing an intensification of the IR-mediated alterations in males. However, the previous studies were performed in adolescents^[@bib54]^ and adults,^[@bib55],\ [@bib56],\ [@bib57]^ where a change in insulin sensitivity was reported according to sex during and after puberty.^[@bib58]^ Thus, they might be not representative of what occurs in prepubertal children.

A further strength of this study is the use of the multiplatform metabolomics strategy, by combining both untargeted (fingerprinting) and targeted (validation) approaches, to investigate the effects of IR in a specific population of obese children matched for sex, age and BMI-SDS naïve to drugs and before puberty, thus avoiding sex steroid influences. In addition, the severity of obesity in the studied patients (mean BMI-SDS above +4.5 SDS in all subgroups) enhances the relationship between the observations and the condition of adiposity excess. Therefore, the use of a multiplatform approach, which magnifies the metabolite coverage by enabling the detection of the main classes of metabolites, provided a more comprehensive overview of the pathways altered as detected by the fingerprinting approach and confirmed in the validation study. However some limitations merit consideration. The sample size was relatively small; although it allowed the detection of validated changes in the whole cohort and in the female subgroup, it might not be sufficient to appreciate differences in the male subgroup for which future studies in a bigger cohort are needed. Moreover, serum was employed in the present study instead of tissue samples due to its easy sampling compared with the invasive modality of tissue collection. Serum provides integrated information regarding processes that are simultaneously occurring in the whole organism as it interacts with all tissues. However, it does not reflect the direct metabolic modifications and upstream regulations in response to external/internal stimuli or life-style modifications (that is, diet and physical activity) that can affect obesity and IR.^[@bib59],\ [@bib60]^ Indeed, it would be of great interest to correlate these results with information regarding nutritional status and habits, physical activity and weight evolution, as well as pre- and peri-natal information including breastfeeding and maternal health. In addition, the use of surrogate measures of IR instead of the gold-standard euglycemic-hyperinsulinemic clamp to discriminate between IR and non-IR patients might be considered a limitation. However, the combined use of fasting and post-OGTT parameters can overcome this limitation, as reinforced by the striking differences in HOMA and insulin-AUC between IR and non-IR subgroups both in groups 1 and 2. Further information on the metabolic/metabolomic status of the patients could eventually be obtained in a future study of the metabolomic profile after high dose oral glucose intake. Moreover, the parallel study of gut microbiota in stool samples could help to explain some of the observed changes reported here.

In conclusion, our study provides new insights into the metabolic profile that characterizes two conditions (obesity and IR) highly associated but not unequivocally correlated to the onset of the disease, by shedding light on the possible pathophysiological alterations that might be hallmarks of the predisposing factors toward complications.
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![Multivariate analysis results (unsupervised, principal components analysis (PCA), and supervised, OPLS-DA, models). (**a**) PCA plot generated from all samples (◊) and QC samples (♦). LC--MS ESI+ data (*R*^2^~(cum)~=0.48, *Q*^2^~(cum)~=0.23). (**b**) OPLS-DA plot generated from the comparison between obese children with IR (▪) and without IR (□). LC--MS ESI+ data (*R*^2^~(cum)~=0.51, *Q*^2^~(cum)~=0.32). (**c**) OPLS-DA plot generated from the comparison between obese children with IR (▴) and without IR (Δ). Only female samples are included to generate the model. LC--MS ESI+ data (*R*^2^~(cum)~=0.99, Q^2^~(cum)~=0.45). *R*^2^= coefficient for variance explained; *Q*^2^= coefficient for variance predicted.](ijo201692f1){#fig1}

![Overview of the changes observed in the metabolic profile of obese children with and without IR. Inflammation and CCM, together with the activity/contribution of the gut microbiota, were found to be altered in obesity-associated hyperinsulinemia. Metabolites that showed significant differences (*P*\< 0.05) between IR and no-IR obese children are depicted in square box. Arrow up: increase; arrow down: decrease relative to control when the whole cohort is investigated. Male (**♂**) and female (**♀**) symbols indicate the metabolites that differ significantly between groups, when boys and girls are considered separately. FAO, fatty acid oxidation; LysoPL, Lysophospholipids.](ijo201692f2){#fig2}

###### Anthropometric and metabolic characteristics of the overall cohort and subgroups (IR and non-IR subjects) that were employed for the fingerprinting (group1) and the validation (group 2) studies

  *Group 1*                        *Overall cohort (*n=*60)*   *IR (*n=*30)*   *Non-IR (*n=*30)*   *Significance*
  ------------------------------- --------------------------- --------------- ------------------- ----------------
  Males/females                              30/30                 15/15             15/15               NS
  Age (years)                              8.56±1.70             8.77±1.87        8.35± 1.72             NS
  BMI-SDS                                  4.75±1.40             4.99±1.45         4.50±1.33             NS
  Fasting glucose (mg dl^−1^)             91.88±5.43            92.80±5.51        90.97±5.28             NS
  Fasting insulin (μU ml^−1^)            15.35± 10.95           21.78±12.32        8.93±2.57         *P*\<0.001
  HOMA index                               3.49±2.40             4,97±2.62         2.01±0.60         *P*\<0.001
  HbA1c (%)                                5.40±0.35             5.38±0.42         5.40±0.35             NS
  AUC-glucose (mg dl^−1^)                248.50±33.28          262.50±34.94      232.35±22.68        *P*\<0.001
  AUC-insulin (μU ml^−1^)                220.05±145.67         329.61±117.18      98.31±33.88        *P*\<0.001
  WBISI                                    1.11±0.65             0.60±0.18         1.70±0.47         *P*\<0.001
  Uric acid                                4.85±1.15             4.96±1.34        4.74± 0.92             NS
  Total cholesterol (mg dl^−1^)          163.45±33.52          162.83±36.03      164.07±31.41            NS
  LDL cholesterol (mg dl^−1^)             99.46±29.49           98.08±30.35      100.85±29.05            NS
  HDL cholesterol (mg dl^−1^)             47.06±12.48           43.24±11.01       50.87±12.88        *P*\<0.05
  VLDL cholesterol (mg dl^−1^)            17.17±12.00           21,61±14.71       12.72±5.96         *P*\<0.01
  Triglycerides (mg dl^−1^)               86.09±60.49          109.28±74.56       63.67±29.89        *P*\<0.01

  *Group 2*                        *Overall cohort (*n=*100)*   *IR (*n=*50)*   *Non-IR (*n=*50)*   *Significance*
  ------------------------------- ---------------------------- --------------- ------------------- ----------------
  Males/females                              50/50                  25/25             25/25               NS
  Age (years)                              7.83±2.70              9.09±2.06         5.25±1.99         *P*\<0.001
  BMI-SDS                                  5.17±2.19              5.10±2.39         5.25±1.99             NS
  Fasting glucose (mg dl^−1^)              92.66±7.36            95.82±7.82        89.50±5.29         *P*\<0.001
  Fasting insulin (μU ml^−1^)              14.59±6.96            20.04±5.23         9.13±3.13         *P*\<0.001
  HOMA index                               3.38±1.72              4.74±1.32         2.02±0.72         *P*\<0.001
  HbA1c (%)                                5.40±0.39              5.52±0.43         5.29±0.31         *P*\<0.01
  AUC-glucose (mg dl^−1^)                 256.42±40.61          271.74±43.02      238.20±28.75        *P*\<0.001
  AUC-insulin (μU ml^−1^)                203.47±113.84          282.61±92.72      106.74±34.50        *P*\<0.001
  WBISI                                    3.38±1.95              1.94±0.49         5.09±1.62         *P*\<0.001
  Uric acid                                4.46±0.85              4.66±0.79         4.26±0.87         *P*\<0.05
  Total cholesterol (mg dl^−1^)           159.47±30.54          162.53±31.60      156.41±29.46            NS
  LDL cholesterol (mg dl^−1^)             96.36±25.44            98.32±27.09       94.39±23.78            NS
  HDL cholesterol (mg dl^−1^)             47.44±12.86            45.59±11.79       49.30±13.71            NS
  VLDL cholesterol (mg dl^−1^)             15.54±8.51            18.60±8.69        12.48±7.19         *P*\<0.001
  Triglycerides (mg dl^−1^)               77.71±42.56            93.02±43.47       62.41±35.97        *P*\<0.001

Abbreviations: AUC, area under the curve; BMI, body mass index; HDL, high-density lipoprotein; HOMA, homoeostasis model assessment; IR, insulin resistance; LDL, low-density lipoprotein; NS, not significant; VLDL, very-low-density lipoprotein; WBISI, whole body insulin sensitivity index.

###### Metabolites identified in the fingerprinting study, which were statistically significant for the comparison between prepubertal obese children with and without IR in M, F and A cohort

  *Metabolite*                 *Cohort*              *Change (%)*
  --------------------------- ---------- -------------------------------------
  Taurodeoxycholate               A         +53[a](#t2-fn2){ref-type="fn"}
                                  M                      +138
  Glycodeoxycholate               A         +76[a](#t2-fn2){ref-type="fn"}
  LysoPE(16:0)                    A         +59[a](#t2-fn2){ref-type="fn"}
                                  F         +54[a](#t2-fn2){ref-type="fn"}
  LysoPC(14:0)                    A         +58[a](#t2-fn2){ref-type="fn"}
                                  F                       +59
  LysoPC(18:3)                    A         +36[a](#t2-fn2){ref-type="fn"}
  LysoPC(22:6)                    F                       −24
  LysoPE(18:0) sn-1               A         +27[a](#t2-fn2){ref-type="fn"}
  LysoPE(18:0) sn-2               A         +28[a](#t2-fn2){ref-type="fn"}
  LysoPE(18:1)                    A                       +32
  LysoPE(18:2) sn-1               A         +32[a](#t2-fn2){ref-type="fn"}
  LysoPE(18:2) sn-2               A         +26[a](#t2-fn2){ref-type="fn"}
  LysoPE(20:3)                    A         +32[a](#t2-fn2){ref-type="fn"}
                                  M                       +59
  LysoPI(16:0) sn-1               M                       +40
  LysoPI(16:0) sn-2               M                       +37
  LysoPI(18:2)                    M                       +22
  LysoPS(18:0)                    F                       −36
  LysoPS(19:0)                    A                       +23
  LysoPS(20:4)                    A         +34[a](#t2-fn2){ref-type="fn"}
                                  F                       +32
  2-Methylbutyroylcarnitine       A                       +25
                                  F                       +28
  Acetylcarnitine                 A                       −20
                                  F                       −24
  Nitro-octadecenoate             F                       −37
  Docosahexaenoate                F                       −33
  Docosapentanoate                A                       −26
                                  F                       −31
  Cer(36:3)                       F                       −32
  Biliverdin                      A                       −10
  Pregnenolone sulphate           F                       −33
  Threitol                        A                       +24
                                  M                       +37
  Piperidine                      A         +18[a](#t2-fn2){ref-type="fn"}
                                  M                       +19
                                  F         +19[a](#t2-fn2){ref-type="fn"}
  Pyruvate                        A                       +46
                                  F         +57[a](#t2-fn2){ref-type="fn"}
  Lactate                         A         +21[a](#t2-fn2){ref-type="fn"}
                                  F         +26[a](#t2-fn2){ref-type="fn"}
  3-Hydroxybutyrate               A         −50[a](#t2-fn2){ref-type="fn"}
                                  M                       −48
  Alanine                         A         +19[a](#t2-fn2){ref-type="fn"}
                                  F         +22[a](#t2-fn2){ref-type="fn"}
  Proline                         A                       +19
                                  M                       +22
  **Valine**                    **A**     **+25** [a](#t2-fn2){ref-type="fn"}
                                  M                       +21
                                  F         +20[a](#t2-fn2){ref-type="fn"}
  Isoleucine                      A                       +20
                                  F         +35[a](#t2-fn2){ref-type="fn"}
  Leucine                         A                       +13
                                  F                       +24
  2-Ketoisocaproate               A                       +17
  **Tryptophan**                **A**                   **+14**
                                  M                       +12
                                  F         +10[a](#t2-fn2){ref-type="fn"}
  Phenylalanine                   A          +9[a](#t2-fn2){ref-type="fn"}
  Tyrosine                        A                       +20
                                  F         +21[a](#t2-fn2){ref-type="fn"}
  Arginine                        A                       +22
                                  F                       +32
  Aspartate                       A                       +16
  Glutamate/ pyroglutamate        F         +19[a](#t2-fn2){ref-type="fn"}
  Ornithine                       A                       +12
  Hypoxanthine                    A                       +18
                                  F                       +28

Abbreviations: A, overall cohort; CE--MS, capillary electrophoresis--mass spectrometry; Cer, ceramide; F, females; GC--MS, gas chromatography--MS; IR, insulin resistance; LC--MS, liquid chromatography--MS; M, males; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine.

Significant in both MVA and UVA. The percentage change refers to obese children with IR compared with children without IR. All metabolites are statistically significant after adjustment for multiple testing (*P*\<0.05); metabolites highlighted in bold are common in more than one analytical technique between LC--MS, GC--MS and CE--MS.

###### Metabolites quantified and confirmed in the validation study for the comparison between prepubertal obese children with and without IR in M, F and A and their concentrations in serum

  *Metabolite*                     *Cohort*                 *Obese without IR*                                 *Obese with IR*                  P*-value*    *Change (%)*
  ------------------------------- ---------- ------------------------------------------------- ------------------------------------------------ ----------- --------------
  Taurodeoxycholate (μg ml^−1^)       A        0.29 (0.14--0.48)[a](#t3-fn2){ref-type="fn"}      0.54 (0.20--0.99)[a](#t3-fn2){ref-type="fn"}   0.049            +86
  Glycodeoxycholate (μg ml^−1^)       A        6.83 (3.39--11.60)[a](#t3-fn2){ref-type="fn"}    10.86 (4.53--20.41)[a](#t3-fn2){ref-type="fn"}  0.016            +59
                                      F        4.84 (3.42--8.45)[a](#t3-fn2){ref-type="fn"}     10.79 (4.51--16.39)[a](#t3-fn2){ref-type="fn"}  0.021            +123
  Piperidine (μg ml^−1^               A                        0.0723±0.0026                                    0.0854 ±0.003                   0.021            +18
                                      F                        0.0649±0.0026                                    0.0839 ±0.0048                  0.009            +29
  Valine (μM)                         A                          125.9±4.4                                        145.5 ±4.7                    0.009            +16
                                      F                          117.8±5.3                                        151.6 ±7.6                    0.0095           +29
  Isoleucine (μg ml^−1^)              A          165 (122--189)[a](#t3-fn2){ref-type="fn"}        188 (161--207)[a](#t3-fn2){ref-type="fn"}     0.025            +14
                                      F          135 (119--185)[a](#t3-fn2){ref-type="fn"}        189 (166--205)[a](#t3-fn2){ref-type="fn"}     0.019            +40
  Leucine (μM)                        A                          83.7±2.5                                          95.3±2.9                     0.016            +14
                                      F                          78.6±3.2                                          95.2±2.9                     0.016            +21
  Phenylalanine (μM)                  A                          77.8±2.0                                          85.7±2.4                     0.037            +10
                                      F                          75.4±2.3                                           85±2.3                      0.049            +13
  Tryptophan (μg ml^−1^)              A                           369±13                                            418±14                      0.028            +13
                                      F                           338±15                                            400±18                      0.022            +18
  Tyrosine (μM)                       A           68 (60--93)[a](#t3-fn2){ref-type="fn"}           90 (69--108)[a](#t3-fn2){ref-type="fn"}      0.016            +31
                                      F                          68.0±3.6                                          86.3±6.5                     0.046            +27
  Pyroglutamate (μg ml^−1^)           A           63 (47--82)[a](#t3-fn2){ref-type="fn"}            56 (51--66)[a](#t3-fn2){ref-type="fn"}      0.037            −10
  Alanine (μM)                        A          265 (224--317)[a](#t3-fn2){ref-type="fn"}        336 (285--400)[a](#t3-fn2){ref-type="fn"}     0.00024          +27
                                      F                           262±10                                            331±14                      0.00030          +27
                                      M          280 (239--333)[a](#t3-fn2){ref-type="fn"}        354 (284--409)[a](#t3-fn2){ref-type="fn"}     0.016            +27
  Proline (μM)                        A          185 (165--211)[a](#t3-fn2){ref-type="fn"}        216 (189--271)[a](#t3-fn2){ref-type="fn"}     0.021            +17
                                      F          184 (158--194)[a](#t3-fn2){ref-type="fn"}        209 (183--260)[a](#t3-fn2){ref-type="fn"}     0.022            +14
  C03-carnitine (μM)                  A                         0.383±0.016                                      0.492±0.024                    0.0067           +22
                                      F                         0.368±0.020                                      0.493±0.035                    0.016            +25
                                      M                         0.398±0.025                                      0.492±0.034                    0.050            +19
  C04-carnitine (μM)                  A        0.17 (0.13--0.21)[a](#t3-fn2){ref-type="fn"}      0.19 (0.16--0.29)[a](#t3-fn2){ref-type="fn"}   0.016            +12
                                      F        0.14 (0.12--0.19)[a](#t3-fn2){ref-type="fn"}      0.20 (0.16--0.33)[a](#t3-fn2){ref-type="fn"}   0.016            +43
  Free-carnitine (μM)                 A       0.030 (0.026--0.035)[a](#t3-fn2){ref-type="fn"}   0.027(0.022--0.032)[a](#t3-fn2){ref-type="fn"}  0.022            −10
  3-Hydroxybutyrate (mM)              A       0.036 (0.021--0.034)[a](#t3-fn2){ref-type="fn"}   0.022(0.019--0.027)[a](#t3-fn2){ref-type="fn"}  0.028            −39
  Pyruvate (mM)                       A        0.23 (0.19--0.27)[a](#t3-fn2){ref-type="fn"}      0.25 (0.21--0.34)[a](#t3-fn2){ref-type="fn"}   0.049            +10

Abbreviations: A, overall cohort; F, females; IR, insulin resistance; M, males.

Non-normal distributed data. Data as mean and s.e.m. in non-normal distributed variable data as median and interquartile range; the change refers to obese children with IR compared with children without IR; *P*-values after adjustment for multiple testing.

[^1]: These authors contributed equally to this work.
